Do genetic variants in NAD(P)H oxidase and multidrug resistance protein modulate the risk of doxorubicin-induced cardiotoxicity?
Genetic polymorphisms in NAD(P)H oxidase and multidrug resistance proteins are associated with the risk of developing doxorubicin-induced cardiotoxicity.
Genetic variants in doxorubicin transport and free radical metabolism may modulate the individual risk to develop ACT.
Wojnowski et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: